http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2307656-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 |
| filingDate | 2006-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_362fc3441d769e0d5c0a1c557d435463 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb86a6668758b59aa91f2c01d775e899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ee64b2274f4eaa2e2b876c668a8ce8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8f24532994fc7158f5a8b36b883c450 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8116ac1e9ff4591b71e4fe618515432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e298acc6822f26f630d6b41f67334e77 |
| publicationDate | 2007-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2307656-C1 |
| titleOfInvention | Method for treating chlamydia-caused prostatitis cases |
| abstract | FIELD: medicine. n SUBSTANCE: method involves administering combined therapy. Azythromycin is introduced at a dose of 1 g once a week as etiotropic therapy during 3 weeks. Ten rectal laser radiation treatment sessions are given beginning from the third combined treatment day. Γ-interferon, interleukin 1β, interleukin 4, interleukin 6 and lactoferrin human blood serum concentrations are additionally measured. Γ-interferon concentration becoming less than 45 IU/ml, that of interleukin 1β growing above 50 pg/ml, interleukin 4 greater than 45 pg/ml, interleukin 6 greater than 60 pg/l and lactoferrin greater than 300 ng/ml, rectal Henferon suppositories are introduced at a dose of 500000 IU twice a day during 14 days. The Henferon treatment course is repeated in 10 days. Ten prostate massage sessions are administered beginning from the twenty first combined therapy day. n EFFECT: enhanced effectiveness in eradicating pathologic agent; prevented infection recurrence; improved spermogram indices; accelerated treatment course; reduced risk of adverse side effects. |
| priorityDate | 2006-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 244.